Home
Careers
Conferences
Directory
Genes
InDepth
Marketing
News
Reports
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Pharmaceutical Market Trends, 2008 - 2012: key market forecasts & growth opportunities
2.
Top-10 Biotech Companies - Market Outlook, 2008-2023
3.
Competitor Analysis: Janus Kinase (JAK) Inhibitors
4.
Enzyme Replacement & Enhancement Therapies (ERT)
5.
The Clinical Laboratory Services Market (Growth Opportunities, Competitive Analysis and Competitor Profiles)
6.
The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
7.
Protein Therapeutics Markets
8.
European Clinical Trial Site Options: An Insiders Analysis Overview
9.
Quality for Biologics
10.
Mammography World Markets
Best Sellers:
1.
Contract Research Annual Review 2008
2.
The Pharmaceutical Wholesale and Distribution Industry Outlook and Analysis 2008
3.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
4.
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts The challenge of turning technology into therapy
5.
Orthopedics - Global Industry Guide
6.
Competitor Analysis: c-MET/HGF Inhibitors
7.
Competitor Analysis: Alzheimers Disease Antibodies
Breakthrough Pain Fast-acting players will capture majority market share
Introduction
In spite of generic Actiq competition, Cephalons reign of the breakthrough pain market will be secured in the short-term with sales of its follow-on brand Fentora. From 2008, however, a number of fast-acting analgesics will enter the arena and battle for market share; this and other growth drivers will see the market more than double from 2005 to reach an estimated $2.5 billion in 2016.
Scope
*Discussion and quantification of the patient potential and market size of breakthrough pain in both malignant and non-malignant diseases
*Assessment of the unmet clinical needs in breakthrough pain as validated by interviewed international opinion leaders
*Detailed overview and assessment of key drugs in Phase II and above clinical development, including Fentora, Rapinyl, and BEMA Fentanyl
*Ten-year sales forecasts to 2016 for key pipeline products
Highlights
Relatively high unmet clinical need, additional patient groups, the launch of new products, and no further key patent expiries within the next ten years will see the breakthrough pain market more than double from 2005 to reach $2.5 billion in 2016.
As well as for oral transmucosal fentanyl products, opportunities also exist for non-oral analgesics. Intranasal and inhaled technology may provide convenient and fast acting analgesia and are potentially suitable for self-administration in the lucrative outpatient setting.
A key growth strategy will be to gain initial approval for cancer breakthrough pain and then drive sales in additional indications through off-label use or regulatory approval. Key non-malignant applications for fast acting analgesics include breakthrough pain in post-operative pain, chronic low back, and osteoarthritic pain.
Reasons to Purchase
*Explore the strategies that have made Cephalon the market leading company in breakthrough pain
*Examine the potential for intranasal and inhaled analgesics and what other factors companies are using to differentiate their products
*Analyze the competitive environment at the time of product launch and identify lucrative gaps in the market
Publication date: 15-Nov-06
Pages: 140
Format: PDF
Table of Contents
Price: $11,400.00 / GBP7,524.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.